1. Home
  2. TLSI vs SAMG Comparison

TLSI vs SAMG Comparison

Compare TLSI & SAMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLSI
  • SAMG
  • Stock Information
  • Founded
  • TLSI 2010
  • SAMG 2002
  • Country
  • TLSI United States
  • SAMG United States
  • Employees
  • TLSI N/A
  • SAMG N/A
  • Industry
  • TLSI Medical Specialities
  • SAMG Investment Managers
  • Sector
  • TLSI Health Care
  • SAMG Finance
  • Exchange
  • TLSI Nasdaq
  • SAMG Nasdaq
  • Market Cap
  • TLSI 160.4M
  • SAMG 155.5M
  • IPO Year
  • TLSI N/A
  • SAMG 2013
  • Fundamental
  • Price
  • TLSI $5.62
  • SAMG $16.47
  • Analyst Decision
  • TLSI Strong Buy
  • SAMG
  • Analyst Count
  • TLSI 6
  • SAMG 0
  • Target Price
  • TLSI $11.75
  • SAMG N/A
  • AVG Volume (30 Days)
  • TLSI 66.8K
  • SAMG 33.8K
  • Earning Date
  • TLSI 03-27-2025
  • SAMG 03-06-2025
  • Dividend Yield
  • TLSI N/A
  • SAMG 4.88%
  • EPS Growth
  • TLSI N/A
  • SAMG 4.17
  • EPS
  • TLSI N/A
  • SAMG 1.00
  • Revenue
  • TLSI $29,431,000.00
  • SAMG $123,651,000.00
  • Revenue This Year
  • TLSI $55.43
  • SAMG $8.52
  • Revenue Next Year
  • TLSI $50.09
  • SAMG $3.95
  • P/E Ratio
  • TLSI N/A
  • SAMG $16.50
  • Revenue Growth
  • TLSI 58.99
  • SAMG 5.32
  • 52 Week Low
  • TLSI $3.50
  • SAMG $13.93
  • 52 Week High
  • TLSI $10.42
  • SAMG $19.20
  • Technical
  • Relative Strength Index (RSI)
  • TLSI 55.78
  • SAMG 38.24
  • Support Level
  • TLSI $5.06
  • SAMG $15.97
  • Resistance Level
  • TLSI $5.72
  • SAMG $16.68
  • Average True Range (ATR)
  • TLSI 0.37
  • SAMG 0.40
  • MACD
  • TLSI 0.03
  • SAMG -0.02
  • Stochastic Oscillator
  • TLSI 90.65
  • SAMG 26.18

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

About SAMG Silvercrest Asset Management Group Inc.

Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.

Share on Social Networks: